You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

Article metrics

Article menu
XML
Emerging technologies, pharmacology and therapeutics
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

 

Online download statistics by month:

Online download statistics by month: December 2020 to March 2024

AbstractFullPdf
Dec 2020260256148
Jan 2021162158122
Feb 202117317175
Mar 202118417467
Apr 202113312842
May 202117117150
Jun 202114514498
Jul 202118317965
Aug 2021307299104
Sep 2021258251113
Oct 202127928099
Nov 202128728782
Dec 202130930657
Jan 202223923282
Feb 202214614452
Mar 202226527182
Apr 202224324298
May 202236836873
Jun 202234633468
Jul 202232232464
Aug 202232532669
Sep 2022423422106
Oct 2022757763104
Nov 202258558561
Dec 202225726145
Jan 202322322261
Feb 202321321443
Mar 202323422976
Apr 202319318466
May 202316015482
Jul 2023243220127
Aug 2023187183110
Sep 2023222196108
Oct 2023255231137
Nov 2023322191129
Dec 2023236128111
Jan 2024166136142
Feb 202421820394
Mar 2024313292173
Total1031298593485